4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Nocturia by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 19 ongoing clinical trials involving Nocturia
Of the 19 trials,12 trials are in Phase IV
Furthermore, 7 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Nocturia by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Nocturia, a Genito Urinary System and Sex Hormones condition. The largest number of ongoing clinical trials for Nocturia is conducted in the Asia-Pacific region. North America and Europe are among some of the other prominent regions engaged in Nocturia-related drug trials.

Ferring International Center SA: The leading ongoing Nocturia related clinical trial sponsor

Ferring International Center SA is the top sponsor for Nocturia-related ongoing clinical trials.

University of South Florida, University College London, Baylor Scott & White Research Institute and National Hospital Organization Kyoto Medical Center are among other notable clinical trial sponsors involved in Nocturia. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Nocturia

Desmopressin acetate (Minirinmelt OD, Noqdirna, Nocdurna), Flavoxate hydrochloride (Urispas / Genurin / Spagerin, Uronid) and Desmopressin acetate (Minirinmelt OD, Noqdirna, Nocdurna) are among the key marketed drugs involving Nocturia.

Desmopressin acetate (Minirinmelt OD, Noqdirna, Nocdurna) is an antidiuretic agent. It functions via Vasopressin V1a Receptor Agonist; Vasopressin V1b Receptor Agonist mechanism of action. Desmopressin acetate is formulated as a disintegrating tablet and lyophilisate for oral route of administration. Desmopressin acetate was first approved in 2011 and is marketed globally in the US, UK, Canada, Germany, and France by several prominent pharma giants including Antares Pharma Inc.

Flavoxate hydrochloride (Urispas / Genurin / Spagerin, Uronid) is a parasympatholytic agent. It functions via Cholinergic Receptor Muscarinic (Muscarinic Acetylcholine Receptor or CHRM) Antagonist mechanism of action. Flavoxate hydrochloride is formulated as film-coated tablets, tablets and solution for oral route of administration. Flavoxate hydrochloride was first approved in 1967 and is marketed globally in UK, France, Belgium, Italy and Spain by several prominent pharma giants including Recordati Ireland Ltd.